Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cefalotin→

Cefalotin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
153-61-7
Molecular formula
C16H16N2O6S2
Molecular weight
396.44 g/mol
Drug class
First-generation parenteral cephalosporin beta-lactam antibacterial
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial cell-wall synthesis by preventing peptidoglycan cross-linking, resulting in bactericidal activity against susceptible organisms.
Indications / reported uses
  • Historically used for treatment of susceptible Gram-positive and selected Gram-negative bacterial infections and perioperative prophylaxis in countries where cefalotin remains authorised; availability and current role are jurisdiction-specific

Sources: NLM MeSH — Cefalotin · PubMed — Cefalotin clinical pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cefalotin Environmental Risk Assessment (ERA) (the Cefalotin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.